ArticleMolecular & cellular oncology2025
Inactivation of Acetyl-CoA Acyltransferase 1 enhances the proliferation and motility of nasopharyngeal carcinoma cells.
Article in Molecular & cellular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetyl-CoA acyltransferase 1 (ACAA1), encoding the peroxisomal 3-ketoacyl-CoA thiolase (POT1), plays a pivotal role in the fatty acid beta-oxidation pathway. Accumulating evidence has linked this enzyme to the onset and development of diverse human malignancies. Here, we observed a marked downregulation of ACAA1 in nasopharyngeal carcinoma (NPC), which displayed an inverse correlation with the expression genes coded by Epstein-Barr virus (EBV). Receiver operating characteristic (ROC) curve and Kaplan-Meier survival analysis highlighted the potential of ACAA1 as a valuable diagnostic and prognostic biomarker for NPC. Next, gain-of- function experiments were conducted, and the results vividly illustrated that overexpression of ACAA1 potently impeded the proliferation, migration, and invasion of NPC cells. The inhibitory effect was further verified by the reduced Ki-67 staining intensity and the altered distribution pattern of actin filaments, which are crucial indicators of cell proliferation and motility. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed significant enrichment of immune-related pathways in NPC cells with elevated ACAA1 expression. Moreover, comprehensive xCell, ESTIMATE, and Immunophenoscore analyses underscored the positive association between ACAA1 and immune cell infiltration and the tumor immune effective microenvironment in NPC. Especially, a positive correlation between ACAA1 expression in tumor cells and six immune checkpoint-related genes, namely CD27, PDCD1, CD86, BTLA, TIGIT, and CD28, on immune cells within the tumor microenvironment. Collectively, our findings highlight the potential of ACAA1 as a tumor - suppressor gene and suggest its possible involvement in the immune evasion mechanisms of NPC. This study may provide novel insights into the molecular pathogenesis of NPC and offer new therapeutic targets for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.